Evommune, Inc.

Equities

EVMN

US30054Y1073

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 06/03/2026 GMT			5-day change	1st Jan Change
26.50 ^USD	+5.62%		+1.92%	+54.79%

03-05	Evommune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-04	Evommune, Inc. announced that it has received $125.300499 million in funding	CI

Evommune Inc on Feb 12, enters securities purchase agreement with investors

Published on 02/13/2026 at 02:21 pm GMT

Reuters

Lock

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

© Reuters - 2026

Latest news about Evommune, Inc.

03-05	Evommune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-04	Evommune, Inc. announced that it has received $125.300499 million in funding	CI
02-13	Evommune Inc on Feb 12, enters securities purchase agreement with investors	RE
02-13	Evommune to Raise $125 Million Via Private Placement	MT
02-11	Evommune, Inc. announced that it expects to receive $125.300499 million in funding	CI
02-10	Top Midday Gainers	MT
02-10	Evommune Says Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial; Shares Rise	MT
02-10	Evommune Says its Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial	MT
02-10	Evommune, Inc. Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis	CI
01-22	Oppenheimer Initiates Coverage on Evommune With Outperform Rating, $42 Price Target	MT
01-08	Raymond James Initiates Coverage on Evommune With Strong Buy Rating, $40 Price Target	MT
01-06	HC Wainwright Initiates Evommune at Buy With $35 Price Target	MT
12-21	Evommune, Inc.(NYSE:EVMN) added to S&P TMI Index	CI
12-19	Aktis Oncology files for US IPO as biotech listings rebound	RE
12-11	Evommune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Chart Evommune, Inc.

Duration

Period

Chart Evommune, Inc.

EVMN: Dynamic Chart

Company Profile

Employees

45

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

8

Last Close Price

26.50USD

Average target price

54.00USD

Spread / Average Target

+103.77%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stock Market News
Evommune Inc on Feb 12, enters securities purchase agreement with investors

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!

BENEFIT NOW